Ketamine Therapy and Its Interaction with Daily Medications
March 8, 2024
Explore why IV ketamine therapy surpasses Spravato ketamine spray for depression and PTSD treatment, with higher success rates, safety, and proven efficacy.
For patients struggling with treatment-resistant depression and other mental health conditions, ketamine therapy has emerged as a groundbreaking treatment option. While both intravenous (IV) ketamine and nasal ketamine spray (esketamine/Spravato) are available treatment modalities, mounting evidence suggests that IV ketamine therapy offers several distinct advantages over ketamine spray administration.
This article examines the key factors that make IV ketamine the superior choice for most patients seeking this innovative treatment. Let’s dive into why in-clinic IV ketamine therapy–such as we provide at Transcend Health Solutions in San Antonio and Austin–is superior to at-home ketamine spray in terms of safety, cost, and patient outcomes.
Ketamine therapy has emerged as a groundbreaking treatment for depression, PTSD, and other mental health conditions, but not all ketamine-based treatments are the same. Two popular approaches—Ketamine-Assisted Psychotherapy (KAP) and Spravato (esketamine) nasal spray—offer different experiences and levels of effectiveness. One of the key distinctions between them is how the medication is administered.
KAP involves receiving intramuscular (IM) or intravenous (IV) ketamine in a controlled clinical setting while being guided by a licensed mental health professional. This method allows for precise dosing and a rapid, full-body absorption of ketamine, leading to a deep, immersive therapeutic experience. During the session, patients are encouraged to explore emotions, memories, and insights with the support of their therapist, making it a truly integrative treatment for mental health.
Spravato, on the other hand, is an FDA-approved nasal spray that contains esketamine, a derivative of ketamine. Patients self-administer the spray under medical supervision in a clinical setting and must remain under observation for at least two hours due to potential side effects like dizziness and dissociation. While Spravato is covered by insurance in some cases, it is limited in dosage and requires multiple sessions per week, making it a more structured yet less personalized approach than KAP.
In the following sections, we’ll explore why KAP offers a more effective, flexible, and holistic treatment experience compared to Spravato.
One of the most significant advantages of IV ketamine over ketamine spray is the precision and reliability of drug delivery. When ketamine is administered intravenously, 100% of the medication reaches the bloodstream, allowing for exact dosing control.
In contrast, ketamine spray absorption through nasal tissues can be highly variable, with bioavailability typically ranging from 25-50%, depending on factors like nasal congestion, proper spray technique, and individual patient anatomy.
The inconsistent absorption of ketamine spray can lead to unpredictable dosing and erratic therapeutic responses. Many patients report that the effectiveness of ketamine spray treatments varies significantly between sessions, while IV administration provides more consistent and reliable results.
IV ketamine begins working almost immediately upon administration, allowing for rapid adjustment of dosing if needed. The healthcare provider can fine-tune the infusion rate in real-time based on the patient's response. When using ketamine spray, however, the absorption delay and variable uptake make it much more challenging to optimize the therapeutic experience.
The controlled delivery of IV ketamine also helps minimize unwanted side effects. If a patient experiences any discomfort, the infusion can be slowed or stopped immediately. Then again, with ketamine spray, once the medication is administered, there's no way to alter its absorption or effects.
While ketamine spray treatments typically require multiple sessions per week in the initial phase, IV ketamine often achieves therapeutic benefits with fewer total sessions. Many patients report significant improvement after 4-6 IV ketamine infusions, whereas ketamine spray protocols may require 8-12 or more initial treatments.
The higher bioavailability of IV ketamine means that less medication is needed to achieve therapeutic blood levels, potentially reducing both costs and side effects. Although individual session costs may be higher for IV treatment, the total course of therapy often ends up being more cost-effective due to fewer required sessions.
Research consistently demonstrates higher response rates and more durable remissions with IV ketamine compared to ketamine spray:
When it comes to mental health treatment, safety is just as important as effectiveness. IV ketamine therapy offers a level of security and precision that ketamine nasal sprays like Spravato simply can’t match. Administered in a carefully controlled medical setting, IV ketamine ensures exact dosing, immediate monitoring, and a personalized approach that prioritizes your well-being. For those struggling with severe depression, PTSD, or anxiety, the peace of mind that comes with a safer, more reliable treatment can make all the difference. Here’s why IV ketamine stands out as the superior choice for safety and support.
For those seeking real relief, versatility matters. While ketamine nasal spray is FDA-approved solely for treatment-resistant depression, IV ketamine therapy has shown powerful results across a much broader spectrum of mental health conditions. From PTSD and severe anxiety to bipolar depression and chronic pain, IV ketamine offers hope where other treatments have failed. With its ability to be tailored to individual needs, this approach provides a lifeline for those who feel like they’ve run out of options. Here’s how IV ketamine goes beyond ketamine spray to offer more possibilities for healing.
When compared to ketamine spray, this versatility makes IV ketamine a more valuable therapeutic tool for practitioners treating patients with complex or co-occurring conditions.
The controlled environment and duration of IV ketamine sessions often provide a more conducive setting for therapeutic breakthrough experiences compared to ketamine spray administration. The typical 40-60 minute IV infusion allows patients to fully process their experience with professional support, while the briefer effects of ketamine spray may not offer the same opportunity for deep therapeutic work.
Unlike ketamine spray, which can be complicated by nasal conditions like congestion, deviated septum, or previous nasal surgery, IV ketamine therapy is not limited by these anatomical factors. This makes IV administration a more universally applicable option for patients who might have difficulty with nasal delivery methods.
Choosing the right treatment isn’t just about effectiveness—it’s about finding what’s safe, reliable, and right for you. While IV ketamine consistently delivers superior results, the best choice depends on individual needs and circumstances. Factors like medical history, symptom severity, and treatment goals all play a role in determining which approach offers the greatest chance for healing and long-term relief. Here’s what to consider when deciding between IV ketamine and ketamine nasal spray.
By carefully weighing important factors such as these, patients and providers can make an informed decision that maximizes both safety and therapeutic efficacy.
As research into ketamine therapy evolves, new findings continue to shape best practices and expand treatment possibilities. The growing body of evidence suggests that IV ketamine may offer superior benefits over ketamine spray, but further studies are needed to refine its use and accessibility. Scientists and clinicians are actively investigating several key areas to enhance patient outcomes.
As these research efforts progress, the future of ketamine therapy promises more precise, personalized, and effective treatment options for those struggling with mental health conditions.
While both IV ketamine and ketamine spray have their place in psychiatric treatment, the evidence strongly supports IV administration as the superior delivery method for most patients. The combination of precise dosing, reliable absorption, controlled therapeutic experience, and demonstrated clinical outcomes makes IV ketamine the gold standard for ketamine therapy.
As the field continues to evolve, healthcare providers should carefully consider these factors when recommending treatment options to their patients. The higher initial cost of IV ketamine therapy is often offset by better outcomes, fewer required sessions, and more durable therapeutic benefits compared to ketamine spray alternatives.
If you’re in San Antonio or Austin and exploring IV ketamine therapy, our experienced team is here to help. We provide personalized treatment plans designed to deliver lasting relief for depression, anxiety, PTSD, and other conditions. Contact us today to schedule a consultation and take the first step toward a more peaceful, productive future.
Abbar, M., Demattei, C., El-Hage, W., Llorca, P.-M., Samalin, L., Demaricourt, P., Gaillard, R., Courtet, P., Vaiva, G., Gorwood, P., Fabbro, P., & Jollant, F. (2022). Ketamine for the acute treatment of severe suicidal ideation: Double blind, randomised placebo controlled trial. BMJ, e067194. https://doi.org/10.1136/bmj-2021-067194
Bahji, A., Vazquez, G. H., & Zarate, C. A., Jr (2021). Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. Journal of Affective Disorders, 278, 542–555. https://doi.org/10.1016/j.jad.2020.09.071
Beaglehole B, Glue P, Neehoff S, Shadhli, S., McNaughton, N., Kimber, B., Muirhead, C., de Bie, A., Day-Brown, R., Hughes-Medlicott, N. J. (2024). Ketamine for treatment-resistant obsessive-compulsive disorder: Double-blind active-controlled crossover study. Journal of Psychopharmacology, 39(1). https://doi.org/10.1177/026988112413012
Canuso, C. M., Singh, J. B., Fedgchin, M., Alphs, L., Lane, R., Lim, P., Pinter, C., Hough, D., Sanacora, G., Manji, H., & Drevets, W. C. (2018). Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: Results of a double-blind, randomized, placebo-controlled study. American Journal of Psychiatry, 175(7), 620-630. https://doi.org/10.1176/appi.ajp.2018.17060720
DeWilde, K. E., Levitch, C. F., Murrough, J. W., Mathew, S. J., & Iosifescu, D. V. (2015). The promise of ketamine for treatment-resistant depression: current evidence and future directions. Annals of the New York Academy of Sciences, 1345(1), 47–58. https://doi.org/10.1111/nyas.12646
Dvorak, L., Bloemhof-Bris, E., Shelef, A., Halperin, D., Wexler, G., Talmon, O., & Feffer, K. (2024). Efficacy of esketamine among patients with treatment resistant depression in a ‘real world' health-care setting in israel. Journal of Psychiatric Research, 174, 66-72. https://doi.org/10.1016/j.jpsychires.2024.04.008
Feder, A., Costi, S., Rutter, S. B., Collins, A. B., Govindarajulu, U., Jha, M. K., Horn, S. R., Kautz, M., Corniquel, M., Collins, K. A., Bevilacqua, L., Glasgow, A. M., Brallier, J., Pietrzak, R. H., Murrough, J. W., & Charney, D. S. (2021). A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder. American Journal of Psychiatry, 178(2), 193-202. https://doi.org/10.1176/appi.ajp.2020.20050596
Fountoulakis, K. N., Saitis, A., & Schatzberg, A. F. (2025). Esketamine treatment for depression in adults: A PRISMA Systematic review and meta-analysis. The American Journal of Psychiatry, appiajp20240515. Advance online publication. https://doi.org/10.1176/appi.ajp.20240515
Gałuszko-Wȩgielnik, M., Włodarczyk, A., Cubała, W. J., Wilkowska, A., Górska, N., & Słupski, J. (2021). Case Report: Repeated Series of Ketamine Infusions in Patients With Treatment-Resistant Depression: Presentation of Five Cases. Frontiers in psychiatry, 12, 705190. https://doi.org/10.3389/fpsyt.2021.705190
Lapidus, K. A., Levitch, C. F., Perez, A. M., Brallier, J. W., Parides, M. K., Soleimani, L., Feder, A., Iosifescu, D. V., Charney, D. S., & Murrough, J. W. (2014). A randomized controlled trial of intranasal ketamine in major depressive disorder. Biological Psychiatry, 76(12), 970–976. https://doi.org/10.1016/j.biopsych.2014.03.026
Ma, X., Yan, J., & Jiang, H. (2023). Application of ketamine in pain management and the underlying mechanism. Pain Research & Management, 2023, 1928969. https://doi.org/10.1155/2023/1928969
Mayo Clinic. (2025, January 1). Esketamine (nasal route). https://www.mayoclinic.org/drugs-supplements/esketamine-nasal-route/description/drg-20458442
Niesters, M., Martini, C., & Dahan, A. (2014). Ketamine for chronic pain: Risks and benefits. British Journal of Clinical Pharmacology, 77(2), 357-367. https://doi.org/10.1111/bcp.12094
Sepulveda Ramos, C., Thornburg, M., Long, K., Sharma, K., Roth, J., Lacatusu, D., Whitaker, R., Pacciulli, D., Moredo Loo, S., Manzoor, M., Tsang, Y. Y., Molenaar, S., Sundar, K., & Jacobs, R. J. (2022). The therapeutic effects of ketamine in mental health disorders: A narrative review. Cureus, 14(3), e23647. https://doi.org/10.7759/cureus.23647
Wells, A. (2024, April 25). Ketamine: A rising star in mental health treatment. Anxiety & Depression Association of America. https://adaa.org/learn-from-us/from-the-experts/blog-posts/consumer-professional/ketamine-rising-star-mental-health
.svg)